R
ecent case reports have linked bisphos phonate drugs to osteonecrosis of the jaw, and these reports have been widely publicized. Many patients receiving these drugs are asking their dentists and doctors whether the drugs do more harm than good, and some have even stopped taking them against medical advice. Health care professionals may be unsure what to tell patients and may be fearful of litigation.
However, most of the cases reported were in cancer patients, who are at significantly higher risk of osteonecrosis of the jaw for several rea sons, and who receive much higher doses of bisphosphonates than do patients with osteo porosis or Paget disease of bone.
Moreover, although case reports have clearly documented an association between these drugs and osteonecrosis of the jaw, there is a lack of robust scientific evidence to support a causeandeffect relationship. In fact, well controlled clinical studies have not shown an increased risk of this complication in patients with osteoporosis or Paget disease of bone who were exposed to these agents, nor have they elucidated definite pathogenic mechanisms by which it might occur.
For these reasons, we believe that patients with osteoporosis should be advised of:
Their risk of fracture • The significant risk of morbidity and death • following such a fracture The effectiveness and excellent safety of bis • phosphonate therapy in preventing fractures The evidence that such therapy for osteo • porosis and Paget disease poses little or no risk of osteonecrosis of the jaw
ReVieW
The need for further research. •
WHAT IS ■ OSTEONECROSIS OF THE JAW?
Osteonecrosis-a general loss of bone tissue as a result of cell death 1 -can occur at any skeletal site, but it typically involves the long bones, ie, the femur, tibia, and humerus.
Osteonecrosis of the jaw is a rare disorder characterized by exposure and loss of bone in the maxillofacial complex. It can result in sig nificant morbidity and can be resistant or re fractory to conventional therapy.
This condition is not new, having been described in 19th century factory workers ex posed to white phosphorus used in matchstick manufacturing. Known then as "phossy jaw," it was associated with poor dentition and often resulted in severe disfigurement, disease, and death. Use of white phosphorus, and matches containing it, were subsequently banned in many countries. 2 In the early 20th century, radiation thera py for cancers of the head and neck area came into vogue, but its side effects included dam age to the skeleton, or osteoradionecrosis. 3 In 1950, LaDow 4 described a case of osteoradio necrosis of the jaw and reviewed the litera ture available at that time. He concluded that there were three main causes of osteonecrosis of the jaw, namely, radiation therapy, trauma, and infection.
Although many such cases have since been reported in association with radia tion therapy, chemotherapy, or both, and involvement of other skeletal sites is well described, 5-8 the actual incidence of osteo radionecrosis in the general population re mains unclear because no large epidemio logic studies to elucidate accurate numbers have been published.
BISPHOSPHONATE-ASSOCIATED ■ OSTEONECROSIS OF THE JAW
Bisphosphonateassociated osteonecrosis of the jaw is a relatively new condition, hav ing been first reported in three case series [9] [10] [11] published in 2003 and 2004. The patients had exposure of areas of alveolar bone, mostly after oral surgery, eg, mucogingival flap elevation procedures (such as tooth extraction), that did not respond or were refractory to conven tional treatment. All had received a bisphos phonate drug. After these articles were published, the number of reported cases rose dramatically, in cluding a case presented by one of us. 12 By the end of January 2008, more than 500 papers on this condition were listed in PubMed. More than 60% had been printed since 2003, and approximately 85% concerned the association between osteonecrosis of the jaw and bispho sphonate use (search terms: "osteonecrosis of the jaw" and "bisphosphonate").
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Although some dentists and oral surgeons claim to have seen many patients with this disorder, physicians who specialize in osteopo rosis and metabolic bone disease do not. The medical literature and popular press have sug gested that bisphosphonates are the cause of this malady. However, such articles are more perspective than evidence, as they are not scientific studies but rather reports of cases or series, or reviews of these. Highimpact jour nals have given such articles prominent po sitions, highlighting the issue further, rather than balancing what is known and what is not known.
Thus, medicine safety boards, physicians, dentists, and oral surgeons have become in creasingly concerned about the possible risk of this disorder in their patients on longterm bisphosphonate therapy, prompting organiza tions to issue management guidelines for this disorder and regulatory bodies to mandate warning labels on all drugs in this class about the possible risk. [14] [15] [16] [17] [18] Funding agencies have highlighted this as an area in need of further investigation. 17 However, robust evidence of a causal rela tionship is lacking. Contributing to the prob lem, other disorders can have similar presen tations.
As a result, the diagnosis requires a dental examination and dental imaging, which are often impossible or impractical in a medical setting. Welldesigned studies have relied on blinded panels of dental specialists using clini cal and imaging data to adjudicate cases as os teonecrosis of the jaw before including them in published reports; case reports, however, often do not.
Many patients are asking whether the drugs do more harm than good
HOW IS OSTEONECROSIS OF THE JAW ■ DIAGNOSED AND MANAGED?
A working definition of osteonecrosis of the jaw has recently emerged, and it will likely continue to evolve as results of further inves tigation become available. A confirmed case is defined as an area of exposed bone in the maxillofacial region that does not heal within 8 weeks after being iden tified by a health care provider, in a patient who is currently receiving or has been exposed to a bisphosphonate and who has not had ra diation therapy to the craniofacial region. 14, 17 This 8week duration is consistent with the time frame in which soft tissue would be ex pected to close and exposed bone would be ex pected to heal under normal conditions after oral surgery such as dental extraction or a flap elevation procedure.
The working definition is one of inclusion and exclusion because the clinical presenta tion of osteonecrosis of the jaw is very similar to that of other diseases (TABLE 1) . 14, 17 It is im portant for health professionals to understand this, since patients who have established os teonecrosis of the jaw or who are deemed to be at risk of it can also present with these other common clinical conditions that should not be confused with it.
Patients may have no symptoms at the time of presentation. However, symptoms can include oral or jaw pain, difficulty chew ing, evidence of infection, and dental loss. Bone loss is often apparent radiographically, and it may be focal or generalized. Other im aging studies such as cone beam computed tomography provide greater detail on the ex tent and nature of the lesions, and thus pro vide a better assessment.
Histologically, there is evidence of ne crosis, cell death, and, usually, concomitant infection. [9] [10] [11] [12] 17 Management can be difficult Osteonecrosis of the jaw can be difficult to manage, and extensive guidelines have been published. [14] [15] [16] [17] Its treatment is complicated be cause resection of the necrotic area often only makes the necrotic area bigger. Unlike in osteora dionecrosis, surgical removal of the affected area often results in necrosis at the margins of resected 
Periapical pathology
Pulpal-periapical response to infection of the dental pulp (eg, caused by caries) bone. This creates a potential situation of "chas ing" affected bone in procedure after procedure, which results in significant morbidity. Staging guidelines provide a framework for treatment (TABLE 2) . 14, 16 Some case studies sug gest that mucoperiosteal flap elevation proce dures such as bone grafting, the use of bone morphogenic proteins, and alveolar bone decortication can succeed, but no randomized, placebocontrolled trials have been conduct ed. 19 Treatment with analgesics, antibiotics, surgery, and hyperbarbic oxygen may also be beneficial. Most authors have concluded that prevention is the ideal approach. [14] [15] [16] [17] [18] [19] [20] A preventive protocol for cancer patients Most of the cases reported so far have been in cancer patients receiving longterm treat ment with potent bisphosphonates in high intravenous doses (12 times the usual dose for osteoporosis) after a mucoperiosteal flap ele vation dental procedure (many of which were performed on an emergency basis).
9-12,14-20 Au thors have thus concluded that a preventive protocol should be followed for all patients be ing considered for intensive bisphosphonate treatment, similar to that adopted for patients receiving head and neck radiation. Specifically, all chronic dental and perio dontal conditions should be identified and stabilized before starting intensive bisphos phonate therapy. Experts today believe that controlling all chronic dental problems before starting intensive intravenous bisphosphonate therapy may be the best method to avoid den tal surgery after bisphosphonate therapy has begun, particularly since the washout period (time to elimination of the drug) for bisphos phonates in alveolar bone is unknown. [14] [15] [16] [17] [18] [19] [20] Although authors seem to agree that such a preventive protocol is prudent for intensive intravenous therapy, it does not appear to be necessary for patients without cancer. 14, 17 In deed, such an approach is impractical, given the huge numbers involved and the lack of evidence to support it. 
These drugs prevent bone resorption by selectively inhibiting osteoclastic activity through several mechanisms (depending on the compound), thus helping prevent bone loss, bone pain, and hypercalcemia in diseases of the skeleton.
Bisphosphonates are widely used Today, oral and intravenous bisphosphonates are widely prescribed for several skeletal disor ders, including metastatic disease, malignant hypercalcemia, Paget disease of bone, and pre vention and treatment of osteoporosis. [21] [22] [23] More than 10 million Americans and more than 200 million people worldwide may have osteoporosis, which results in more than 1 million fractures each year. The lifetime risk of fracture for a postmenopausal white woman today is approximately 40% (approximately 15% for a 50yearold man), and her annual risk of fracture is greater than her combined risk of stroke, heart attack, and breast cancer. 22 Several bisphosphonates have been shown to safely and significantly reduce the risk of frac ture in patients with osteoporosis and to be ef fective therapies for Paget disease of bone. [24] [25] [26] [27] [28] [29] [30] [31] Bisphosphonates are the most widely pre scribed drugs for osteoporosis, 22, 23, 29 with almost 200 million prescriptions for oral bisphos phonates worldwide. As of 2004, exposure to alendronate (Fosamax) was estimated to be about 20 million patientyears. 32 Noncompli ance limits their effectiveness in practice, due in part to concerns about adverse effects.
Since bisphosphonates are so widely pre scribed, concern has been raised that they may be causing a new epidemic of osteonecrosis of the jaw. 9 However, most reported cases have been in cancer patients, who are known to be at increased risk of this condition and who re ceive doses of bisphosphonates up to 12 times higher than in patients with osteoporosis or Paget disease of bone. [9] [10] [11] [12] [33] [34] [35] [36] [37] [38] The optimal duration of bisphosphonate therapy for these diseases to obtain the maxi mum benefit and minimize cost and harm re mains unclear. Although a recent report sug gests a bisphosphonate "drug holiday" may be an option when treating postmenopausal osteoporosis, larger, more robust studies of longer duration are needed. 39 Outcomes of os teonecrosis of the jaw related to drug holidays have not been investigated.
'IF I TAKE THIS TO STOP BONE LOSS, ■ WILL IT HURT My JAWS?'
The recently described association between bisphosphonates and osteonecrosis of the jaw has received considerable attention. Guide lines have been drawn up, some based on the assumption that bisphosphonates cause the osteonecrosis, but not based on scien tific research. [14] [15] [16] [17] [18] More than 90% of reported cases have been in cancer patients, a group known to be at increased risk of osteonecrosis of the jaw and other skeletal sites, for reasons that include radiation therapy, chemother apy, corticosteroid use, and increased risk of infections. 4, 6, [9] [10] [11] [12] [33] [34] [35] [36] [37] [38] Nevertheless, it has been assumed that these patients are the same as os teoporosis patients, and sometimes that causa tion is beyond dispute. This is problematic for two main reasons:
Since noncompliance and lack of adher • ence (due to lack of knowledge about the dangers posed by osteoporosis, cost of the drugs, difficulty with dosing regimens, and fear of adverse effects) limit the effective ness of these therapies in clinical practice, such attention has already persuaded pa tients to discontinue or refuse therapy (J.J. Carey, personal experience and communi cations from colleagues); and Patients with osteoporosis and osteoporot • ic fractures have increased rates of morbid ity and mortality and significantly higher Some guidelines are based more on assumptions than on science
The washout period for bisphosphonates in alveolar bone is unknown fracture risk, which can be prevented with these agents if they are willing to take them.
Association does not prove causation
However, association does not prove causa tion. A relationship between a drug and a disease may be due to chance alone or to con founding factors. 40 To judge the exact nature of this relationship, several issues need to be considered when reviewing the available evi dence.
Substantiating that an agent causes a disease requires careful consideration of sev eral aspects of their relationship: temporality, strength, doseresponse, reversibility, consis tency, biologic plausibility, and specificity. 41 Correct interpretation of the strength of the evidence should also incorporate an evalu ation of the study design, size, and reporting mechanism. Accordingly, case reports and case series are considered to constitute the weakest evidence, while randomized controlled trials and metaanalyses are usually considered the strongest.
When a true causeandeffect relationship does exist, the situation can be a simple one in which only a single agent is involved. How ever, the issue can be decidedly more complex when the cause is an effectmodifier, requiring the interaction of additional factors.
When a cause has been assumed, demon stration of the doseresponse relationship is also important: whether the risk is related in a continuous fashion to dose and duration of therapy (all patients), is seen only with partic ular doses or regimens (such as frequent use of high doses of potent bisphosphonates), or ex ists only in people who have passed a certain threshold value (for example, it may only oc cur in those who have received 0.5 g of an in travenous or 10 g of an oral bisphosphonate). Bearing in mind these considerations, the na ture of the relationship between an agent and a disease can be better understood.
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A cause-and-effect relationship has not been established A causeandeffect relationship between bis phosphonates and osteonecrosis of the jaw has not been clearly established. 14, 17 Although case series highlight a relationship between the two, large controlled trials evaluating the occurrence of osteonecrosis of the jaw as the primary outcome have not been conducted. To date, most cases have been reported as un controlled case series, generally considered the weakest form of evidence. 43 
Most cases have been in cancer patients
Most cases of osteonecrosis of the jaw were in patients with cancer (particularly breast can cer and multiple myeloma) receiving potent intravenous bisphosphonates in high doses, most of whom had other documented risk fac tors, including recent dental procedures such as tooth extraction. [9] [10] [11] [12] [15] [16] [17] [18] [19] [33] [34] [35] [36] [37] [38] One of the most compelling studies sup porting causation examined the prevalence of osteonecrosis of the jaw in a cohort of 303 my eloma patients from 1991 to 2003. Osteone crosis of the jaw developed only in those tak ing bisphosphonates (28 of 254), and the risk appeared greatest in those treated with both zoledronic acid (Zometa) and thalidomide (Thalomid). The importance of additional chemotherapies, concomitant diseases, and baseline dental pathology was not described. 35 Biases, including channeling bias (in which patients who appear at increased risk of this rare condition also appear to be most likely to receive this medication), referral bias, and survivor bias, were not addressed in this paper or in others claiming that the risk is related to the type of bisphosphonate used and the dura tion of its use. 15, [33] [34] [35] [36] [37] [38] A review of all cases of osteonecrosis of the jaw over a 5year period in one institu tion (N = 163) found that only 17 (10%) were associated with bisphosphonate use, and all 17 patients had other risk factors, such as concomitant therapy for malignan cy and recent dental surgery. 34 The authors' concern that longer followup may have shown a higher incidence of this problem is supported by the temporal relationship seen in other reports in which cancer patients with osteonecrosis of the jaw appear to have had higher cumulative doses of intravenous bisphosphonates than those without. 9-12 ,15,34,35,37,38 Unfortunately, only one study had a control group to highlight the incidence of osteonecrosis of the jaw in similar pa tients not treated with bisphosphonates.
The incidence in cancer patients treated with intravenous bisphosphonates has been reported as between 0% and 11%, and the incidence is higher following dental proce dures and with a greater duration of drug exposure. 11, 14, 15, 17, 35, 38, 44 Interestingly, in a recent survey of oncolo gists prescribing bisphosphonate medications for metastatic indications, twothirds said they believe their patients probably have un diagnosed chronic oral conditions that could increase the risk of osteonecrosis of the jaw following bisphosphonate therapy and dental surgery procedures. A similar number reported that their patients receive routine dental care (access to and cost of dental care and the dif ficulty in physician prescreening are cited as obstacles), but only about onethird actually refer their patients to dentists before starting bisphosphonate therapy.
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What recent studies in osteoporosis and Paget disease showed Controlled scientific studies in osteoporosis and Paget disease of bone have not shown osteonecrosis of the jaw to emerge, even af ter years of treatment with bisphosphonate drugs. [24] [25] [26] [27] [28] [29] [30] [31] [46] [47] [48] [49] To date, more than 50,000 pa tients have been treated with oral bisphos phonates-more than 100,000 patientyears for each drug: alendronate, risedronate (Ac tonel), and ibandronate (Boniva)-in clini cal trials, and there has not been a single case of bisphosphonateassociated osteonecrosis in any of these studies. 48 Recent publications have addressed the results of clinical trials comparing zoledron ic acid (the drug most often associated with this condition in published case series) and risedronate in more than 300 patients with Paget disease of bone, 31 and with placebo in postmenopausal women with osteoporosis and persons over 50 years of age suffering a hip fracture treated for up to 3 years following their fracture. 29, 30 In the largest trial, almost 4,000 osteo porotic women were treated with 5 mg of zoledronic acid annually for 3 years, and a similar number received placebo. Despite a rigorous search for any potential cases of bis phosphonateassociated osteonecrosis of the jaw-adjudicated by a blinded panel of ex perts on the basis of clinical and dental diag nostic imaging-only two possible cases were found: one in the placebo group and one in the treatment group (a case of osteomyelitis that preceded any treatment with zoledronic acid). Both patients recovered following a course of oral antibiotics and debridement. There was no increase in osteonecrosis at other skeletal sites. 29, 49 Observational studies have yielded con flicting results. An Australian postal survey of oral surgeons and dentists combined with drug adverse events data suggested the fre quency of osteonecrosis of the jaw was 1:2,260 to 1:8,470 in patients on weekly alendronate treatment for osteoporosis, and 1:56 to 1:380 in patients with Paget disease. Following den tal extractions, this rose to 1:296 to 1:1,130 and 1:7.4 to 1:48, respectively. Results in pa tients with malignancy were similar to those in other studies. 44 The study raises issues simi lar to those in other studies: lack of an appro priate control group, reporting bias, and the possibility of multiple reportings of the same patients.
Unpublished information from pharma ceutical companies has suggested the inci dence of unconfirmed cases of osteonecrosis of the jaw in persons taking alendronate is 0.7/100,000 personyears. 14, 17 One study using administrative claims data did not find evi dence of increased bisphosphonate use in pa tients undergoing jaw surgery (used as a sur rogate for osteonecrosis of the jaw), 50 while another actually found that oral bisphospho nates had a protective effect against osteone crosis of the jaw, inflammatory conditions of the jaw, and need for major jaw surgery.
51
The risk, if any, is probably very small This information suggests that if these drugs, used at the recommended dose, really do pose a risk, it is probably very small: less than 1 case in 100,000 patientyears if taking an oral bisphosphonate such as alendronate. 14, 17 This is significantly less than the risk of fracture in these patients (which may be higher than 1 in 10), the risk of death following such a fracture, [22] [23] [24] [25] [26] [27] [28] [29] [30] or the risk of death from drown ing, house fire, or motor vehicle accident. 52 The cases of osteonecrosis of the jaw that we have personally seen-all in cancer pa More than 50,000 patients in clinical trials received these drugs for osteoporosis or paget disease, and none got osteonecrosis
The risk is significantly less than the risk of death following a hip or vertebral fracture tients treated with chemotherapy and high dose bisphosphonates-all showed histologic evidence of necrosis and concomitant infec tions, suggesting the actual diagnosis was os teomyelitis. Bone biopsies from affected but macroscopically normal mandibles at the time of surgical debridement for osteonecrosis of the jaw showed normal or increased osteo clastic activity, in contrast to what one would expect if there were oversuppression of bone turnover (unpublished data, J. Christian, J. Carey, Cleveland Clinic).
Recently, this family of drugs has shown some promise in limiting the progression of al veolar bone loss in periodontal disease (though they are not approved for this indication). [53] [54] [55] Finally, published studies suggest bisphospho nate therapy may even be beneficial in ani mals and humans with osteonecrosis, [56] [57] [58] and in conditions that mimic osteonecrosis such as SAPHO syndrome (synovitis, acne, pustulo sis, hyperostosis, and osteitis) of the mandible, in which the histologic appearance may re semble that of osteonecrosis. Prevention will likely be the most effec • tive management strategy because of the significant morbidity associated with and the refractory nature of osteonecrosis of the jaw. Prophylactic dental examinations and any • needed repair work are probably best done before starting bisphosphonate therapy in cancer patients; however, studies support ing such a strategy are needed. There is no evidence to support routine • dental examinations before starting such therapy for disorders other than cancer, or for stopping such therapy before, during, or after dental surgery. Whether this is true for patients who have been taking these drugs for several years or more is unclear. Good communication between patients • and their physicians, dentists, periodon tists, and surgeons will help provide them with the best possible care. Clearly, much further research is needed on the causes, risks, diagnosis, and management of this disorder to optimize patient outcomes. ■
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WHAT SHOULD WE TELL OUR PATIENTS? ■
